Â鶹Éç

Available for over a year

Each year more than 2 million men and women die from work-related accidents and diseases according to the International Labour Organisation. Assessing risk is notoriously tricky in any business. Are there lessons for companies like BP, from the medical world whose systems regularly analyse costs against the benefits of treatment? Lesley Curwen asks Sir Michael Rawlins, the chairman of NICE, the UK's National Institute for Health and Clinical Excellence. Plus, how do governments weigh up the health risks of substances such as asbestos, against the economic cost of banning such an industry? We ask Rupert Younger, Director of the Oxford Centre for Corporate Reputation at the Saïd Business school. And Mark Tully reports from Delhi on India's suspicion of cheap Chinese goods.